Cimetidine Use and the Risk for Prostate Cancer: Results From the VITAL Cohort Study
BERKELEY, CA (UroToday.com) - Previously, it was suggested that men filling greater than 20 cimetidine prescriptions were at increased risk of developing prostate cancer (CaP). Cimetidine, but not other H2 blockers, can inhibit dihydrotestosterone from binding to androgen receptors and increase levels of estradiol.
 | Written by Christopher P. Evans, MD, a Contributing Editor with UroToday. |
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence
Privacy Policy | © 2010 UroToday ® All Rights Reserved |
